PosterSessionOnline

ESMO WORLD CONGRESS ON GASTROINTESTINAL CANCER

ESMO World Congress on Gastrointestinal Cancer

30 June - 3 July 2021 Virtual Conference

N. Poster

Poster title

Applicant name

Status


SO-1	The impact of COVID-19 on daily practice patterns in the third-line setting for patients with metastatic colorectal cancer: Results of a real-world survey	Joanne Franklin	Received

PD-1	MOUNTAINEER: Open-label, phase 2 study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress)	Natalie Pizzimenti	Received

P-1	Health-related quality of life of rectal cancer survivors treated with curative intent	André Ferreira	Received

P-2	First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: A cost-effectiveness analysis	Sik Kwan Chan	Received

PD-2	Final result of phase IB study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer	Richard Kim	Received

SO-3	Treatment sequences and prognostic factors in metastatic pancreatic ductal adenocarcinoma: Univariate and multivariate analyses of a real-world study in Europe	Julien Taieb	Received

PD-3	Impact of RAS status, prior targeted therapy, age, and gender on the activity of aflibercept plus FOLFIRI in patients with metastatic colorectal cancer: Real-world data from the QoLiTrap study	Roger von Moos	Received

P-3	Gastric cancer: 10-year survival	Oleg Kshivets	Received

P-4	Prognostic and therapeutic values of tumor-infiltrating lymphocytes in localized colon cancer	sonia Ben Nasr	Received

O-4	Average cumulative relative dose of adjuvant chemotherapy is more important than average relative dose intensity for colorectal cancer survival, with implications for treating obese patients: The OCTOPUS consortium	Corinna Slawinski	Received

SO-4	Progression-free survival in patients With cholangiocarcinoma with FGFR2 fusions or rearrangements: A FIGHT-202 post-hoc analysis of prior systemic therapy response	Ghassan Abou-Alfa	Received

LBA-5	Phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer	Zev Wainberg	Received

PD-5	Retrospective comparative analysis of K-ras G12C vs other K-ras mutations in metastatic colorectal cancer patients treated with first-line chemotherapy doublet bevacizumab	Riccardo Giampieri	Received

SO-5	Tumor inflammation and proliferative status as biomarkers in gastroesophageal adenocarcinoma	Sarbajit Mukherjee	Received

P-5	The use of complementary and alternative medicine among colorectal cancer patients in Tunisia	sonia Ben Nasr	Received

O-6	Gene alterations in ctDNA related to the resistance mechanism of anti-EGFR antibodies and clinical efficacy outcomes of anti-EGFR antibody rechallenge plus trifluridine/tipiracil in metastatic colorectal cancer patients in WJOG8916G trial	Naoki Izawa	Received

P-6	Spatio-temporal distribution pattern of pancreatic cancer mortality rate in Peru between 2003-2017	Claudio Flores	Received

PD-6	Prediction of patients at high risk of upper gastrointestinal cancer for endoscopy using artificial intelligent technology	Yiguang Lin	Received

SO-6	Microarchitectural changes in regional lymph nodes after chemotherapy in oesophageal cancer: Results from the UK MRC OE02 trial	Maximilian Kloft	Received

O-7	FOLFIRI napabucasin in patients with previously treated metastatic colorectal cancer: Overall survival results from the phase 3 CanStem303C study	Manish A. Shah	Received

P-7	How much can GIT cancer patients afford for effective and safe treatment?	Rasha Aboelhassan	Received

SO-7	The prognostic and predictive role of preoperative chemotherapy sensitivity in gastric adenocarcinoma: A study of national cancer database	Lei Deng	Received

P-8	Nutritional status among colorectal cancer patients in Tunisia	sonia Ben Nasr	Received

P-9	Prognostic role of preoperative inflammation parameters in predicting postoperative complications of colorectal cancer surgery.	sonia Ben Nasr	Received

SO-9	Analysis of the immune-related endpoints of the mismatch repairdeficient non-endometrial solid cancers cohort from the GARNET study	Thierry André	Received

SO-10	An open-label, multi-centre, phase Ib/II study of PI3K ive inhibitor GSK2636771 administered in combination with paclitaxel in patients with advanced gastric cancer having alterations in PI3K/Akt pathway	Minkyu Jung	Received

P-10	Prevalence and risk factors of chronic neuropathy in 225 colorectal cancer patients treated with oxaliplatin-based regimens in Tunisia	sonia Ben Nasr	Received

P-11	GAME score in patients with liver metastases from colorectal cancer	Wala Ben Kridis	Received

O-11	Monitoring molecular residual disease by circulating tumor DNA in resectable colorectal cancer: Molecular subgroup analyses of a prospective observational study GALAXY in CIRCULATE-Japan	Hiromichi Shirasu	Received

P-12	Long intergenic non-protein coding RNA 1094 regulates the progression of gastric cancer	Ouyang Ge	Received

O-12	Phase II study of preoperative chemoradiotherapy plus avelumab in patients with locally advanced rectal cancer: The AVANA study	Lisa Salvatore	Received

P-13	Efficacy of FOLFOX4 regimen with advanced hepatocellular carcinoma and prognostic factors for survival	Chawalit Chayangsu	Received

SO-13	KRAS-G12C mutations in a Nordic cohort of 1441 metastatic colorectal cancer patients	Emerik Osterlund	Received

O-13	Gut microbiome to predict survival time in advanced gastric cancer treated with nivolumab: The DELIVER trial (JACCRO GC-08)	Yu Sunakawa	Received

P-14	The predictive value of alkaline phosphatase and lactate dehydrogenase for overall survival in patients with pancreatic cancer	bengueddach aicha	Received

O-14	Exploratory biomarker analysis of trastuzumab deruxtecan in DESTINY-Gastric01, a randomized, phase 2, multicenter, open-label study in patients with HER2-positive or -low advanced gastric or gastroesophageal junction adenocarcinoma	Kohei Shitara	Received

SO-14	The prognostic impact of KRAS G12C mutation in patients with metastatic colorectal cancer: A multicenter retrospective observational study	Yuki Matsubara	Received

SO-15	Quality of life and physical functioning in older patients with metastatic colorectal cancer receiving palliative chemotherapy: The randomized NORDIC9-study	Gabor Liposits	Received

P-15	Diagnostic potential of erythrocyte and serum fatty acids in spotting adenomatous polyps and identifying the early stages of colorectal cancer depending on tumor localization	Margarita Kruchinina	Received

P-16	How does reinduction of first-line chemotherapy in patients with metastatic colorectal cancer impact outcomes? Experience from the University Hospital for Tumors, Zagreb, Croatia	Mirjana Pavlovic	Received

SO-16	Quality of life in Finnish metastatic colorectal cancer patients actively treated with the aim of maximizing resection and/or local ablative therapy (RAXO-study NCT01531595)	Pia Osterlund	Received

P-17	CT colonography: A minimally invasive screening option for colorectal cancer	Jagmeet Grewal	Received

SO-18	Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: Final results according to duration of treatment from the phase IIIb, international, open-label, early-access PRECONNECT study	Julien Taieb	Received

P-18	Phase Ib study of niraparib plus tebotelimab in patients with advanced or metastatic gastric cancer after prior treatment failure	Bo Lyu	Received

SO-19	A multicenter phase II trial of trifluridine/tipiracil in combination with cetuximab in RAS wild-type metastatic colorectal cancer patients refractory to prior anti-EGFR antibody therapy: The WJOG8916G trial	Naoki Izawa	Received

P-19	Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres followed by Gemcitabine plus Cisplatin for Treatment of Intra-hepatic Cholangiocarcinoma: A Phase 2 Single-Arm Multicenter Clinical Trial	Stephen Lam Chan	Received

SO-20	Prospective validation of Ang-2 and Tie-2 plasma levels as predictors of benefit from regorafenib in metastatic colorectal cancer patients: REGOLAND study.	Carlotta Antoniotti	Received

P-20	Concurrent chemo-radiotherapy in anal squamous cell carcinomas: A 10-year retrospective review of a tertiary centre experience	Abdelfattah Elmasry	Received

SO-21	Impact of timing of perioperative chemotherapy on survival outcomes among patients with colorectal liver metastases: A propensity score matching of the national cancer database	Firas Baidoun	Received

P-21	Real-world outcomes in patients with advanced or metastatic gastric adenocarcinoma in the United States	Daniel Beachler	Received

P-22	Role of timing to laparoscopic or robotic surgery after neoadjuvant chemoradiotherapy for rectal cancer: The TiMiSNAR trial	Igor Monsellato	Received

SO-23	The genomic temporal heterogeneity of circulating tumor DNA in metastatic colorectal cancer under first-line treatment	Feng Wang	Received

P-23	Experience of concurrent chemoradiotherapy for pancreatic cancer in a large university hospital	Gemma Searle	Received

P-24	A prospective phase 1b dose de-escalation open-label clinical study to evaluate the safety and efficacy of sorafenib with metformin and atorvastatin in advanced hepatocellular carcinoma (SMASH)	PRABHAT BHARGAVA	Received

SO-24	Circulating tumor DNA variant allelic fraction as a surrogate for disease burden estimation in patients with RAS wild-type metastatic colorectal cancer: A secondary endpoint of the VALENTINO study	Paolo Manca	Received

SO-25	Global rise in early-onset colorectal cancer: An association with antibiotic consumption?	Sarah Perrott	Received

P-25	A review of circulating exosomal biomarkers in the diagnosis of pancreatic cancer	Menazir Sha	Received

SO-26	In-silico Lynch syndrome-related neoantigens prediction for a dendritic cell-based cancer prevention vaccine	Cristina Bayó	Received

P-27	The efficacy and safety of XELOX/SOX plus bevacizumab as neoadjuvant chemotherapy for locally advanced rectal cancer compared with XELOX/SOX: A retrospective study	Nanako Sakaguchi	Received

SO-28	Effect of prior bevacizumab treatment in BRAF V600E-mutant metastatic colorectal cancer: Overall survival with encorafenib cetuximab /- binimetinib in BEACON CRC	Michele Springer	Received

P-28	Exploratory analysis of patients with gastric/GEJ adenocarcinoma with or without liver metastasis from the phase 3 RAINBOW study	yui okada	Received

SO-29	Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion-positive gastrointestinal cancer: an expanded dataset	Valentina Boni	Received

P-29	Pancreatic cancer during the COVID-19 pandemic: A high-volume Polish centre experience	Karolina K&281;dzierska-Kapuza	Received

SO-30	Efficacy and safety of neoadjuvant short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma: Averectal study	Ali Shamseddine	Received

SO-31	ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer	Hyun Cheol Chung	Received

P-31	Real-world efficacy and safety of trifluridine/tipiracil plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies	Nieves Martinez Lago	Received

P-32	SARS-CoV-2 pandemic and delayed presentation of gastrointestinal cancer patients: A retrospective evaluation and the impact on clinical outcome	Budhi Ida Bagus	Received

P-33	Results of initial DPYD screening for cancer patients receiving fluoropyrimidines	Matilde Bolaños	Received

P-34	Real-world efficacy and safety of immune checkpoint inhibitors in microsatellite unstable or mismatch repair deficient gastrointestinal tumors	Nieves Martinez Lago	Received

P-35	HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of first-line treatment.	Ken Ito	Received

P-37	SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations: Biliary tract cancer cohort (trial in progress)	Tanios Bekaii-Saab	Received

P-38	Unmet needs and concerns of Russian patients with CRC: Analysis of Russian internet postings	Aleksandr Krotkevich	Received

P-39	The role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib	Margherita Rimini	Received

P-40	Lenvatinib versus sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study	Margherita Rimini	Received

P-42	Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies as treatment option in vulnerable older patients with metastatic colorectal cancer: A retrospective cohort study	Gerardo Rosati	Received

P-43	C677T and A1298C MTHFR gene polymorphisms and response to fluoropyrimidine-based chemotherapy in mestizo patients with metastatic colorectal cancer.	Allan Ramos-Esquivel	Received

P-44	Expression and clinical significance of B cell translocation gene 2 in esophageal squamous cell carcinoma	Wanpeng Wang	Received

P-45	An open-label, phase 2 study of patritumab deruxtecan in patients with previously treated advanced/metastatic colorectal cancer	Kanwal Raghav	Received

P-46	Integrated transcriptomics and the exploration of cancer-promoting genes CDKN3 in esophageal squamous cell cancer	Yan Pan	Received

P-47	5-fluorouracil bolus use in infusional regimens among oncologists: A survey by Brazilian Group of Gastrointestinal Tumors	RENATA PEIXOTO	Received

P-48	Study of paclitaxel and ramucirumab as second-line therapy after failure of FOLFOX-6 regimen in metastatic stomach carcinoma patients	Varun Goel	Received

P-49	Oesophageal neuroendocrine carcinoma: retrospective evaluation of outcomes from a UK tertiary centre	Michael Tilby	Received

P-50	Prognostic factors in patients receiving trifluridine/tipiracil for refractory metastatic colorectal cancer in the real-life setting: The ROS study	Esther Álvarez-García	Received

P-51	Baseline characteristics of patients enrolled in the CAPSTAN study: A European retrospective study in BRAFV600E-mutant metastatic colorectal cancer patients	Erika Martinelli	Received

P-52	Overall survival with cetuximab every 2 weeks vs standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumor location	Stefan Kasper	Received

P-53	Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis	Rachel Broadbent	Received

P-54	Higher muscle mass is associated with better response to concurrent neoadjuvant chemoradiotherapy in rectal cancer patients	Kiril Zhelev	Received

P-55	Constructing a Hybrid Control for the MORPHEUS Colorectal Cancer (CRC) Trial Using IMblaze370 Historical Trial Data	Neil Segal	Received

P-56	A multicenter prospective translational study using circulating tumor DNA to identify acquired genomic alterations in recurrent gastric or gastroesophageal junction adenocarcinoma in patients who received curative-intent treatment (Liquid-GEAR)	Hiroyuki Takeda	Received

P-57	US real-world ramucirumab and immune checkpoint inhibitor (ICI) treatment sequences in advanced gastric, gastroesophageal junction, or esophageal cancer.	Julie Beyrer	Received

P-58	Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: A multi-centric, multi-national, prospective, longitudinal, non-interventional study in Germany and Austria BERING CRC	Frank Reichenbach	Received

P-60	Doxycycline as preventive treatment of skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy	Juan Luis Sanz	Received

P-61	Relatlimab nivolumab in patients with advanced hepatocellular carcinoma who are naive to immuno-oncology therapy but progressed on tyrosine kinase inhibitors, a phase 2, randomized, open-label study: RELATIVITY-073	Kathryn Woods	Received

P-62	Overall survival of patients with pancreatic cancer	Claudio Flores	Received

P-63	MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer - randomised, double-blind, placebo-controlled, Phase 3 study	Yelena Yuriy Janjigian	Received

P-64	The?impact of?sarcopenia?on overall survival?among?cholangiocarcinoma patients: A systematic review?and meta-analysis	Jeannette Tandiono	Received

P-65	Expression of TIMP-1 level as a diagnostic and prognostic factor in colon cancer patients: A systematic review	Jeannette Tandiono	Received

P-66	Experience in our center of bone events not related to the disease in patients with locally advanced or metastatic adenocarcinoma of the pancreas	INMACULADA GALLEGO JIMENEZ	Received

P-67	Prognostic implication of HER2 overexpression in surgically treated patients with gastric cancer	Erkhembayar Enkhbat	Received

P-68	Response to neoadjuvant chemotherapy in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma with FLOT-regimen in our setting	Clara Garcia Grove	Received

P-69	Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience.	Alessandro Rizzo	Received

P-70	First-in-human study of highly ive FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors	Cori Ann Sherwin	Received

P-71	KRYSTAL-10: A randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation	Josep Tabernero	Received

P-72	A Patient Preference Study on Risk Thresholds to Switch Between Daily Tablets and Biweekly Infusions in Second-Line Treatment for Advanced Hepatocellular Carcinoma	Neehar Parikh	Received

P-73	The role of site of metastatic resection in metastatic colorectal cancer patients: A mono-institutional cohort study	Floriana Camarda	Received

P-74	The impact of first-line chemotherapy in elderly patients with advanced pancreatic cancer: A mono-institutional retrospective study	Maria Grazia Maratta	Received

P-75	Impact of an educational activity on the knowledge of oncologists regarding the latest clinical trial data on HER2-directed therapies for gastric and colorectal cancer	Nabil Dorkhom	Received

P-76	Effect of educational activity on the knowledge of oncologists regarding the latest clinical trial data investigating immunotherapy combination regimens for the frontline treatment of patients with unresectable HCC	Nabil Dorkhom	Received

P-78	Post hoc analysis in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function in the phase 3 REFLECT study of lenvatinib vs sorafenib	Jasmine Huynh	Received

P-79	HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of second-line treatment after anti-EGFR antibody	Ken Ito	Received

P-80	Sorafenib in extended patient populations in real-world clinical practice: Baseline characteristics from OPTIMIS and GIDEON	Open Health Open Health	Received

P-81	HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of second-line treatment	Ken Ito	Received

P-82	Impact of type 2 diabetes mellitus in overall survival and clinical features of Latin patients with colorectal cancer: A 15-year follow-up	German Calderillo	Received

P-83	The efficacy of chemotherapy for gastric cancer with early recurrence during or after adjuvant S-1	Koshi Kumagai	Received

P-84	Genotype-fenotype correlation in patients with Lynch syndrome and colorectal cancer	Jose Angel García-Cuesta	Received

P-85	Relationship between microsatellite instability and neoadjuvant chemotherapy response in gastric or gastroesophageal junction cancer: A meta-analysis	Selin Akturk Esen	Received

P-86	The importance of sphingosine kinase 1 isoform expression in the gut-liver axis	Hongjie Chen	Received

P-87	Real-world data of nivolumab in advanced hepatocellular carcinoma: A multi-centric and retrospective study	Mariana Sardinha	Received

P-89	The correlation between adverse events and survival benefits of donafenib in the first-line treatment of advanced hepatocellular carcinoma	Feng Bi	Received

P-90	Combined high expression of MAP17 and fascin-1 in colorectal cancer: Targeted therapy in need?	Athanasios Tampakis	Received

P-91	Safety and efficacy of perioperative FLOT in elderly patients: Real-world data	Mafalda Baleiras	Received

P-92	The neuroendocrine tumor diagnostic process and the role of gastrointestinal specialists	Simone Leyden	Received

P-93	The characteristics and prognosis of extragastrointestinal stromal tumors: A single center retrospective analysis of 31 patients	Mingchun Mu	Received

P-94	Unicentric real-world data from esophageal cancer neoadjuvant treatment according to the CROSS trial protocol	Joana Mendona	Received

P-95	EV-202: An open-label, multicenter, phase 2 study of enfortumab vedotin in patients with previously treated locally advanced or metastatic solid tumors, including upper gastrointestinal cancers	Kei Muro	Received

P-96	Analysis of three biographical times of disease in the IMbrave 150 study: A new measure to assess clinical effect	Eduardo Ceballos Barbancho	Received

P-97	Updated results of HGCSG1603: a phase 2 trial of ramucirumab plus irinotecan combination therapy as second-line treatment for patients with advanced gastric cancer	Michio Nakamura	Received

P-98	A single-arm study of apatinib plus neoadjuvant chemotherapy followed by resection in patients with locally advanced colorectal adenocarcinoma	Aimin Zhang	Received

P-99	Circulating RNA detection, circulating tumor cells count (CTC) and molecular tumor profiling in a cohort of untreated metastatic colorectal cancer: A prospective multicenter ancillary study to the randomized VISNÚ trials	Susana Rodríguez	Received

P-100	A phase II study of first-line chemotherapy initiating FOLFIRIcetuximab and switching to FOLFIRIbevacizumab according to early tumor shrinkage at 8 weeks in RAS wild-type metastatic colorectal cancer: HYBRID trial	Hirokazu Shoji	Received

P-101	Survival of early-onset gastric signet ring cell carcinoma in the Korean population between 2010 and 2015: Analysis of the Korean central cancer registry database	Hee Man Kim	Received

P-102	The importance of maintenance chemotherapy in the first and second lines of treatment of metastatic colorectal cancer	Danila Gridnev	Received

P-103	Associations between quality-of-life, symptom burden, and demographic characteristics in long-term esophageal and gastroesophageal junction cancer survivors	Erin McGillivray	Received

P-104	Risk of nausea and vomiting in a real-world data cohort of chemotherapy-treated patients with metastatic gastric or gastroesophageal junction adenocarcinoma by medical history of gastrectomy	Stefan de Vogel	Received

P-105	POLO: patient-centred outcomes with maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer	Hedy Kindler	Received

P-106	Descriptive study of long-term survivors with advanced pancreatic cancer	Victoria Aviño Tarazona	Received

P-107	Dermatopathological review of cutaneous squamous cell carcinoma events in patients with gastrointestinal stromal tumors treated with ripretinib	Anisha Patel	Received

P-108	Circulating tumor DNA for early relapse detection and monitoring disease status in patients with early-stage pancreatic adenocarcinoma	Maen Abdelrahim	Received

P-109	CYTOFLOC: Evaluation of a non-endoscopic immunocytological device (Cytosponge) for post-chemo-radiotherapy surveillance in patients with oesophageal cancer a feasibility study	Somnath Mukherjee	Received

P-110	Is dexamethasone necessary as a prophylactic antiemetic prior to gemcitabine plus nab-paclitaxel therapy?	Shiho Murata	Received

P-111	PERSPECTIVE: Tepotinib plus cetuximab in patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer and acquired resistance to anti-EGFR antibody therapy due to MET amplification	Syneos Health	Received

P-112	Compliance analysis of biological samples and questionnaire collection in a colorectal cancer microbiome study: the VHIO experience	stefania napoli	Received

P-113	FIGHT-302: Phase 3 study of first-line pemigatinib vs gemcitabine cisplatin for cholangiocarcinoma with FGFR2 fusions or rearrangement	Ulita Nonemaker	Received

P-114	Claudin 18 isoform expression in gastric adenocarcinoma and pancreatic adenocarcinoma	Takeshi Saito	Received

P-116	What have we learned about of trifluridine/tipiracil (TAS-102)? Real World Data at four GEODA hospitals (Spain)	JULIA MARTÍNEZ PÉREZ	Received

P-117	Survival Outcomes following Systemic Chemotherapy in Stage IVA/B High-grade Mucinous Appendiceal Cancer after Unsuccessful Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy	Ekaterina Baron	Received

P-118	Survival Outcomes of Adjuvant Chemotherapy in Stage IVA/B High-grade Appendiceal Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy	Ekaterina Baron	Received

P-119	Impact of circulating tumor DNA on clinical decisions in the adjuvant setting in patients with colorectal cancer	Vanessa Wookey	Received

P-120	Pre-assessment tool predicting complication following oesophagogastric resection: Sarcopenia or incremental shuttle walk test	Yashashwi Sinha	Received

P-121	Efficacy and toxicity of biosimilar and original bevacizumab in the second-line treatment of metastatic colon cancer in routine clinical practice: Results of an observational multicenter study	Mikhail Fedyannin	Received

P-122	Gastrointestinal side effects of morphine in cancer pain: A comparison between the smoking and non-smoking patients	Fatima Zahra Hijri	Received

P-123	Survival analysis based on the grade of neutropenia in patients with metastatic colorectal cancer treated with trifluridine-tipiracil	Victoria Aviño Tarazona	Received

P-124	Nivolumab plus ipilimumab as neoadjuvant therapy for potentially resectable hepatocellular carcinoma	Yung-Yeh Su	Received

P-125	Caring for more than survival: A survey of patient preferences in advanced hepatocellular carcinoma	Siu Hing Lo	Received

P-126	Atezolizumab plus bevacizumab for patients with advanced hepatocellular carcinoma and chronic hepatitis B virus infection with high viral load	Chiun Hsu	Received

P-127	Lymphocyte to monocyte ratio as a prognostic factor in stage IV pancreatic ductal adenocarcinoma naive patients before gemcitabine-nab-paclitaxel chemotherapy	Andrea Pretta	Received

P-128	Influence of anti-diabetic medications on the outcomes of patients with pancreatic ductal adenocarcinoma and type 2 diabetes mellitus	Andrea Pretta	Received

P-129	Concomitant RAS and BRAF mutations: impact on overall survival and progression free survival in metastatic colorectal cancer patients	Andrea Pretta	Received

P-130	Real-world outcomes of patients with colorectal liver metastases treated with transarterial radioembolization: Results from CIRT, a large European, prospective multi-centre, observational study	Niklaus Schaefer	Received

P-131	External validation of prognostic ALAN score in patients with inoperable bile duct cancer treated with second-line chemotherapy	Riccardo Giampieri	Received

P-132	Molecular profiling of KIT and PDGFRA in Chilean GIST patients: A Latin-American perspective	Matias Muñoz-Medel	Received

P-133	The watch-and-wait approach in stage IV rectal cancer patients: A good alternative for TME surgery?	Petra Custers	Received

P-134	Social determinants of health are risk factors for early onset colorectal cancer in Appalachia	William Oelsner	Received

P-135	Pembrolizumab/quavonlimab coformulation in combination with lenvatinib in advanced hepatocellular carcinoma: Phase 2 trial in progress	Daneng Li	Received

P-136	Detecting panitumumab/FOLFOX responders in K-Ras wild-type metastatic colorectal cancer through an artificial intelligence-based analytical tool	Carlos Galmarini	Received

P-137	Patient baseline characteristics in the PROMETCO study: A real-world, prospective longitudinal cohort on the continuum of care of metastatic colorectal cancer	Miriam Koopman	Received

P-138	Margetuximab combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) /- chemotherapy in first-line therapy of advanced/metastatic HER2 gastroesophageal junction or gastric cancer	Daniel Catenacci	Received

P-139	A phase 2 multicohort study (LEAP-005) of lenvatinib plus pembrolizumab in patients with previously treated ed solid tumors: Pancreatic cancer cohort	Hyun Cheol Chung	Received

P-140	A phase I study of biweekly abraxane in combination with oxaliplatin and oral S-1/leucovorin as first line treatment for advanced gastric, pancreatic and biliary tract cancers	Hi-Jen Tsai	Received

P-141	Neoadjuvant chemotherapy with docetaxel, nedaplatin, and 5-FU for resectable esophageal cancer: A single center retrospective study	Satoko Shindo	Received

P-142	Safety and efficacy of apatinib for non-surgical advanced esophageal cancer: A real-world study	Hongfei Zhang	Received

P-143	Polyphyllin ? and resiquimod-loaded injectable hydrogels promote the polarization of tumor-associated macrophages and enhance gastric cancer immunotherapy	Hanqing Qian	Received

P-144	A comparative analysis of secondary data from the ToGA and EVIDENCE studies on the effectiveness of trastuzumab plus chemotherapy in Asian patients with HER2 metastatic gastric cancer	Ying Wu	Received

P-145	Doublet regimen plus anti-vascular endothelial growth factor drug regimen after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer	Toshihiko Matsumoto	Received

P-146	Clinical usefulness of next generation sequencing by liquid biopsy for advanced gastric cancer	Toshihiko Matsumoto	Received

P-147	Epigenetic gene somatic mutations in gastric cancer	Alexey Kalinkin	Received

P-148	Perfect concordance between blood-based and normal tissue-based dihydropyrimidine dehydrogenase polymorphisms suggests that pharmacogenetic screening could be contextual to tumour molecular profiling	Cristina Morelli	Received

P-149	Integrative analysis of the genomic and transcriptomic landscape identifies novel key genes as a therapeutic target in bile duct cancer	Massimiliano Salati	Received

P-150	Insights into the gastric and oesophageal cancer patient experience: Results of a pan-European patient survey	Zorana Maravic	Received

P-151	The prognostic value of TCF1CD8T cell in primary small cell carcinoma of the esophagus	Lin Ma	Received

P-152	Sarcopenia in advanced colorectal cancer patients treated with trifluridine/tipiracil	Mateusz Malik	Received

P-153	Safety and effectiveness of sorafenib in elderly patients diagnosed with advanced hepatocellular carcinoma in a monographic oncologic center	Zara Vidales Sepulveda	Received

P-154	A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy compared with chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015	Josep Tabernero	Received

P-155	A phase I study of FLOT as first-line therapy for Japanese patients with advanced gastric cancer including patients with or without severe peritoneal metastasis	Kazuhiro Shiraishi	Received

P-156	A European chart review of treatment patterns and outcomes for patients with resected esophageal cancer or gastroesophageal junction cancer	Prianka Singh	Received

P-157	Assessing fitness for systemic therapy in hepatocellular carcinoma: Evaluating time on treatment according to Child-Pugh classification, model for end-stage liver disease score, and AFP level	Benjamin Staum	Received

P-158	Deciphering the immunological determinants of response to neoadjuvant chemo-radiation in esophageal adenocarcinoma	Giuseppina Arbore	Received

P-159	HERIZON: Phase 2 part of the IMU-131 HER2/neu vaccine plus chemotherapy study randomized in patients with HER2/NEU overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction	Rita Laeufle	Received

P-160	Young Latin American population with colorectal cancer: Characteristics of bad prognosis	German Calderillo	Received

P-161	The diagnostic methods for detection of Helicobacter pylori infection: A comparative approach to invasive methods.	Fabian Castro-Valencia	Received

P-162	Universally adopted Vitamin D deficiency cutoff of 10 ng/mL is optimal for metastatic colorectal cancer prognostication and corrleated with neutrophil/lymphocyte ratio	michela rofei	Received

P-163	Real-world outcomes of cisplatin, capecitabine and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first-line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma	Nadia Hitchen	Received

P-164	MONEO: A phase II study of avelumab plus FLOT in the peri-operative treatment for patients with resectable gastric or gastroesophageal junction cancer	Maria Alsina	Received

P-165	Comparative study on the clinical effect of hand-assisted laparoscopic and laparoscopic gastrectomy for gastric stromal tumor	Qu-xia Zhang	Received

P-166	Operative versus nonoperative treatment for stage 0 rectal cancer following chemoradiation therapy	Fatima Aurora Aires	Received

P-167	Efficacy of PD-1 inhibitors for colorectal cancer and polyps in Lynch syndrome patients	Binyi Xiao	Received

P-168	Differences in coping strategies used by colorectal vs. non-colorectal cancer patients: Data from the Neoetic-SEOM study	Vilma Pacheco-Barcia	Received

P-169	Tumor-infiltrating lymphocytes in colorectal cancer: A clinical outcome predictor	Marina Vitorino	Received

P-170	Assessment of long-term outcomes and predictive factors of malignancy in branch-duct intraductal papillary mucinous neoplasms: A retrospective study in a Canadian referral center	Anas Chennouf	Received

P-171	Does metastasectomy really improve survival in gastric cancer?	Marcelle Cesca	Received

P-172	PTHrP and SPARC expressions in human colorectal cancer: An in silico analysis	Pedro Matías Carriere	Received

P-173	Customisation of therapeutic strategy in metastatic colorectal cancer by use of liquid biopsies: Final results of an observational study	Myrto Kastrisiou	Received

P-174	MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2 gastric or gastroesophageal junction adenocarcinoma: Trial in progress	Natalie Pizzimenti	Received

P-175	Effectiveness, prognostic factors and safety concerning ablative techniques in liver metastases from gastrointestinal tumors	Martín Igor Gómez-Randulfe Rodríguez	Received

P-176	A multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin with or without CPI-613 as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-04)	Vaibhav Sahai	Received

P-177	Early onset colorectal cancer outcomes in a public Uruguayan cancer centre	Santiago Fontes	Received

P-178	Rego-Nivo for the treatment of HCC refractory to chemotherapy after the 2nd line	yasmina ben merabet	Received

P-180	Rectal cancer in the elderly: Characteristics, management and outcomes from a single centre retrospective cohort review	Ruba A Hamed	Received

P-181	Exploratory randomized phase II trial for optimizing treatment dosage and duration of adjuvant S-1 plus oxaliplatin in patients with stage III colon cancer (SOAP trial)	SUWA YUSUKE	Received

P-182	A multicenter study of prognostic factors in nivolumab monotherapy for advanced or recurrent esophageal cancer	Tatsuki Ikoma	Received

P-183	Laparoscopic colorectal resection for elderly patients aged 80 years or older: A propensity score analysis	Ryo Inada	Received

P-184	Underlining mechanism for the efficacy of tumor treating fields (TTFields) concomitant with sorafenib for treatment of hepatocellular carcinoma	Adi Haber	Received

P-185	A prospective, randomized, controlled, multicenter phase III clinical trial of apatinib combined with neoadjuvant chemoradiotherapy for patients with locally advanced, HER2-negative, Siewerts type II-III adenocarcinoma of esophagogastric junction	Qun Zhao	Received

P-186	Vimentin-positive circulating tumor cells as diagnostic and prognostic biomarkers in biliary tract cancer patients	Sung Yong Han	Received

P-187	Watch-and-wait strategy for DNA mismatch repair-deficient/microsatellite instability-high rectal cancer with a clinical complete response after neoadjuvant immunotherapy: An observational cohort study	Qiao-xuan Wang	Received

P-188	Propensity score analysis of outcomes following laparoscopic or open radical resection for gallbladder carcinoma in T2 and T3 stages	changwei dou	Received

P-189	Safety and feasibility of liposomal irinotecan for unresectable pancreatic adenocarcinoma: Real-world experience in a Japanese cohort	Ayano Sakai	Received

P-190	Exploring possible predictors of survival in hepatocellular carcinoma	Ins Eiriz	Received

P-191	Prognostic factors of colorectal cancer liver metastasectomy	Ins Costa	Received

P-192	Chemoradiation for anal canal carcinoma: A multicentric retrospective cohort study	Ines Leao	Received

P-193	Final results of hepatectomy followed by adjuvant chemotherapy with 3-month capecitabine plus oxaliplatin for colorectal cancer liver metastases: A multicenter phase 2 study	Hiroki Hashida	Received

P-194	Study of efficacy and safety of combination of octreotide acetate LAR with lenvatinib as second-line therapy in patients with advanced G1-G2 NETs of non-pancreatic origin	varun goel	Received

P-195	Gastric adenocarcinoma classification: Association with clinicopathological features and overall survival in Moroccan patients	Jean Paul NSHIZIRUNGU	Received

P-196	Frequency, biological behaviour and survival nomograms discrimination in non-KIT mutated gastrointestinal stromal tumors	Tiago Alpoim	Received

P-197	The influence of proton pump inhibitor utilization on the pathological response of rectal cancer: A multicenter study by the Sociedad Latino Americana de Oncologia Gastrointestinal (SLAGO)	Marcelle Cesca	Received

P-198	Prevalence of deleterious DPYD variants in patients with gastrointestinal malignancies: Real-world data from a single institution in Italy	CLAUDIA CARDONE	Received

P-199	Baseline neutrophil to lymphocyte ratio predicts survival in patients with metastatic colorectal cancer treated with cetuximab plus avelumab (CAVE) as a rechallenge strategy	Davide Ciardiello	Received

P-200	A phase II study of dose reductive XELOX plus bevacizumab in elderly or vulnerable patients with metastatic colorectal cancer: MCSGO-1202	Ken Nakata	Received

P-201	Retrospective evaluation of patients with colorectal cancer with metastasis in the central nervous system: Clinical and epidemiological prognostic factors	Marcelle Cesca	Received

P-202	Primary tumour location and efficacy of first-line anti-EGFR agents in the treatment of RAS wild-type metastatic colorectal cancer	Joana Marinho	Received

P-203	Relationship of myelotoxicity and of gastrointestinal toxicity with the treatment outcome in trials of second-line chemotherapy of patients with metastatic colorectal cancer	Antonella Venturino	Received

P-204	Survival improvement from the addition of biologics is not affected by performance status in patients with metastatic colorectal cancer: A meta-analysis	Giuseppe Colloca	Received

P-206	Survival comparison of first-line therapies in locally advanced or metastatic pancreatic cancer: A Portuguese oncology unit experience	Rita Gameiro-dos-Santos	Received

P-207	FLOT in clinical practice: Retrospective analysis of an oncological center	Raquel Fontes	Received

P-208	Pancreatic neuroendocrine neoplasia: Experience of a comprehensive cancer center	Sara Coelho	Received

P-209	Cancers of the bile duct: A study of 30 cases	benamar wassila	Received

P-210	Capecitabine and temozolomide for metastatic neuroendocrine neoplasms: A single-center real-word data analysis	Ana Caetano	Received

P-211	Risk of diabetes in subjects with positive fecal immunochemical test: A nationwide population-based study	Hyun Jung Lee	Received

P-212	The genetic and epigenetic abnormalities of plasma cfDNA as liquid biopsy biomarkers for diagnosis and prognosis stratification of pancreatic ductal adenocarcinoma	Ruijingfang Jiang	Received

P-213	Helicobacter pylori babA gene evolution and adaptation in Colombian populations	Kevin Guzman	Received

P-214	Should patients with active gastrointestinal tumors receive thromboprophylaxis to avoid the negative clinical consequences of CAT? Sub-analysis of ACT4CAT study	Nikolaos Tsoukalas	Received

P-215	Short-term results and survival outcomes following resection of localized pancreatic neuroendocrine tumors: a brazilian single center experience.	Dante Arra	Received

P-216	Gender-specific genomic alterations among Hispanic patients with metastatic colorectal cancer	Sayed Reshad Ghafouri	Received

P-217	The knowledge and awareness for colorectal cancer in advanced colorectal cancer patients in China: A national multicenter study	HUIFANG XU	Received

P-218	STAT3 signaling inhibition in regulatory T cells improves immune response to RT in PDAC	Miles Piper	Received

P-219	Real-life experience with chemotherapy plus biologics in first-line treatment of right-sided, RAS wild-type, metastatic colon cancer: A multicenter Onco-Colon Turkey study	Cagatay Arslan	Received

P-221	Repurposing disulfiram as treatment for metastatic colorectal cancer: An investigator-initiated clinical phase I/II trial	Line Tarpgaard	Received

P-222	Dihydropyrimidine dehydrogenase deficiencies and fluoropyrimidine toxicities: A study in the Tunisian Center	Melliti Rihab	Received

P-223	Gasdermin B predicts good prognosis and more macrophage infiltration	liang Sun	Received

P-224	Expression of major components of the exosome biogenesis pathway is deregulated in colorectal cancer and associated with clinical outcome: Preliminary results from an association study	Anastasia Kottorou	Received

P-225	Clinico-epidemiological and therapeutic profile of rectal cancer: Experience of the department of radiation oncology EHSO ORAN	meriem cheriguene	Received

P-226	Trifluridin/tipiracil and regorafenib sequencing in Slovenian patients with metastatic colorectal cancer	Tanja Mesti	Received

P-227	Comparative safety and tolerability of approved PARP inhibitors in cancer: A systematic review and network meta-analysis	Zhaolun Cai	Received

P-228	Phase II multicentric randomized controlled trial to compare first-line treatment with FOLFOX6m mAB alone or in combination with liver chemoembolization (Lifepearls-Irinotecan) in poor prognosis colorectal cancer with liver-limited disease	Anna Virgili	Received

P-229	Systematic review and pooled analysis of locoregional therapies in patients with intrahepatic cholangiocarcinoma	Julien Edeline	Received

P-230	Is stereotactic microwave ablation of resectable colorectal liver metastasis an alternative for liver resection in the Covid-19 pandemic?	Thiery Chapelle	Received

P-231	Systemic inflammatory biomarkers and their association with survival in gastroesophageal cancer patients: A retrospective single-center analysis	Hannah Christina Puhr	Received

P-232	Prognostic inflammatory and microRNA biomarkers in stage IV colorectal cancer patients	Sally Temraz	Received

P-233	Patient information and management by eHealth intervention during colon cancer	Melina Campagnaro	Received

P-234	Participation of screening and barriers in Chinese patients with advanced colorectal cancer before diagnosis: A national multi-center cross-sectional study	Yin Liu	Received

P-235	E-health monitoring during pancreatic cancer treatment	Melina Campagnaro	Received

P-237	Clinical doctors attitudes towards colorectal cancer genetic testing: A national multi-center cross-sectional study	Yin Liu	Received

P-238	Clinicopathological profile and prognostic factors impacting survival of periampullary carcinoma: A tertiary care centre experience	ADITYA KUMAR SINGLA	Received

P-239	Consensus molecular subtypes of morphological regions on colorectal tumors	Vlad Popovici	Received

P-240	The diagnosis and treatment of advanced colorectal cancer in China: A national multi-center cross-sectional study	HUIFANG XU	Received

P-243	A prospective study to assess the impact of colostomy on psychosocial aspects of quality of life in colorectal cancer patients	Divya Khosla	Received

P-244	Role of preoperative contrast-enhanced computed tomography in staging of gastric cancer in patients undergoing upfront surgery with curative intent	Lalchhandami Colney	Received

P-245	Evaluation of colon-specific plasma nanovesicles as new markers of colorectal cancer	Inga Nazarova	Received

P-250	Epidemiological, diagnostic and therapeutic profile of pancreatic cancer: Experience of a medical oncology department	Somia Chaibdra Tani	Received

P-252	Residual fibrosis after treatment with anti-epidermal growth factor receptor or bevacizumab in colorectal liver metastases and its correlation with survival: A retrospective pooled analysis	Xavier Hernández-Yage	Received

P-253	Detection of potential molecules that might be implicated in colorectal metastasis to lung	Panagiotis Apostolou	Received

P-255	The clinical significance of the gut microbiota in RAS wild-type metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies in combination with chemotherapy - preliminary results	Pawe&322; Stelmasiak	Received

P-256	Fibroblast-induced paradoxical PI3K pathway activation in colorectal cancer: Role of PTEN and potential implications for PI3K/mTOR inhibition	Chiara Bazzichetto	Received

P-258	Clinical study of PD-1 disrupted anti-MUC1 CAR-T cells in patients with advanced oesophageal cancer	Size Chen	Received

P-261	Phase I study of multiple kinase inhibitor, TT-00420, in advanced, refractory cholangiocarcinoma	Sarina Piha-Paul	Received

P-262	Highly sensitive quantification of Extracellular Vesicles Derived From Colorectal Cancer	Nadezhda Nikiforova	Received

P-263	The effects of co-administration of erlotinib and apatinib in the treatment oesophageal squamous cell carcinoma	Yiguang Lin	Received

P-264	Helicobacter pylori SNPs associated with tetracycline, clarithromycin and amoxicillin resistance in Colombia	Kevin Guzman	Received

P-265	Neoadjuvant radiotherapy for locally advanced rectal cancer during the first wave of COVID19 pandemic: Guys cancer cohort experience	Kasia Owczarczyk	Received

P-266	Oncological outcomes of self-expanding metal stents as a bridge to surgery for obstructive left-sided colon cancer	Laura Gomez Fernandez	Received

P-267	Interleukin-8 levels as a predictor of colorectal cancer patient prognosis	Fabiana Conciatori	Received

P-268	Seaweed laminaria japonica peptides possess strong anti-liver cancer effects	Hongjie Chen	Received

P-269	Advanced gastric cancer bleeding: Association of hemostatic radiotherapy and iron supplementation - Is there a survival benefit?	André Laranja	Received

P-270	Impact of intestinal stoma on quality of life in Tunisian patients with colorectal cancer	NOUHA AMMAR	Received

P-271	The anti-tumor effect of Curcuma phaeocaulis cyclopeptide in human hepatoma HepG2 cells	Hongjie Chen	Received

P-272	Significance of adding oxaliplatin to postoperative adjuvant chemotherapy in elderly patients with colorectal cancer	Yusuke Nagata	Received

P-273	Mucinous colorectal cancer in Tunisian patients: A controversial clinicopathological type	Haifa TOUNSI GUETTITI	Received

P-274	Exploratory analysis of potential clinical, molecular and analytical prognostic factors of real-world patients with gastrointestinal stromal tumors: A single center study	Ignacio Perez Criado	Received

P-275	Evaluation of radical chemoradiation outcomes in stage II/III anal cancer: Real-world data population	Isabel Fernandes	Received

P-278	Checkpoint Inhibitors in Patients with Advanced, Refractory Biliary Tract Cancers	Savannah Liddell	Received

P-279	Thromboembolic complications in colorectal cancers	nassima mkedder	Received

P-280	HEPANOVA: Final efficacy and safety results from a phase 2 study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma	Robert Merker	Received

P-281	Low proliferation indexes in colorectal cancer in Tunisian patients: Association with rectal localization, mucinous histological type and stage	Dorra Wider	Received

P-282	Factors predicting response to neoadjuvant chemotherapy in gastric cancer	Pavan Kumar C G	Received

P-283	Prognostic factors in the evaluation of stage II/III squamous cell carcinoma of the anus treated with chemoradiation	João Gramaa	Received

P-284	Exploratory magnetic resonance imaging histogram biomarkers for response prediction to neoadjuvant treatment in oesophageal/gastro-oesophageal cancer	Kasia Owczarczyk	Received

P-285	Treatment outcomes with sorafenib in advanced hepatocellular carcinoma: A single-center retrospective study	Juraj Prejac	Received

P-286	Assessment of the quality of life of patients with colorectal cancer in the Tunisian Center: A report of 142 patients	Imtinene Belaid	Received

P-287	Preclinical evaluation of alpelisib (PI3K inhibitor ) and its synergistic effect in combination with ribociclib (CDK 4/6 inhibitor) in colorectal cancer	razia aslam	Received

P-288	Individual drug-screening and heterogeneity analyses of patient-derived tumoroids: A roadmap to improving therapy in pancreatic cancer	Christine Nitschke	Received

P-289	Gastric and esophageal signet ring cell adenocarcinoma: A retrospective analysis of outcomes at Mayo Clinic	Zhubene Mesbah	Received

P-290	Mutant allele specific imbalance in RAS as prognostic marker in colorectal cancer	Nirit Yarom	Received

P-291	The prognostic and predictive factors for patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy	Banu Ozturk	Received

P-292	Tumor downstaging as an associated factor with recurrence of disease in patients with operated rectal cancer after neoadjuvant chemoradiotherapy: Real-world data from Peru	Rodrigo Motta	Received

P-294	Impact of surgical margin status on the survival outcome after surgical resection of gastric cancer: A systematic review and meta-analysis	Zhiyuan Jiang	Received

P-295	The importance of sphingosine kinase 1 isoform expression in the gut-liver axis	Hongjie Chen	Received

P-296	Establishment of adoptive cell therapy with tumor-infiltrating lymphocytes for liver and oesophageal cancer	Shuzhi Ma	Received

P-297	Upfront dihydropyrimidine dehydrogenase deficiency detection to secure 5-FU or capecitabine administration: Application to colorectal cancer patients	nassima mkedder	Received

LBA-298	Response to Total Neoadjuvant Therapy and Survival in Patients with Early Onset Locally Advanced Rectal Cancer	Melissa Lumish	Received

ESMO World Congress on Gastrointestinal Cancer

30 June - 3 July 2021 Virtual Conference

About us

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 30/04/2021 TO 30/06/2023

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access